Home / Products / Genome-edited Cells / PCDH9 Knockout HEK293T Cell Line

PCDH9 Knockout HEK293T Cell Line

Cat. No. ARG44027
Product Type:

In Stock Cell Lines

Species:

Homo sapiens (Human)

Tissue Source:

Kidney

Growth Properties:

Adherent

In stock
Request a Quote

Short Description 🔒

The PCDH9 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited human cell line lacking protocadherin-9. Loss of this calcium-dependent adhesion protein disrupts homophilic interactions and downstream signaling through beta-catenin and Rho GTPases such as RAC1 and CDC42. Based on high-transfectability HEK293T cells, this line enables robust functional studies including cell adhesion, migration, and TOP/FOP Flash reporter assays. Applications encompass tumor suppressor research, neurodevelopmental disease modeling, and protein?Cprotein interaction analysis, providing a precise tool for dissecting protocadherin-9 function in signal transduction.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Kidney
Growth Mode:
Adherent
Age:
Fetus
Sex of Donor:
Female
Derived From Site:
Fetal kidney
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
HEK293T
Gene Name:
PCDH9
Gene Identifier:
NCBI Gene ID 5101

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The PCDH9 Knockout HEK293T Cell Line is a human knockout cell line generated by CRISPR/Cas9-mediated disruption of the PCDH9 gene, encoding protocadherin-9. This stable loss-of-function model provides an isogenic system for investigating PCDH9-dependent cellular processes in a defined genetic background.

The parental HEK293T cell line is a human embryonic kidney line transformed with SV40 large T antigen, exhibiting adherent epithelial morphology and exceptionally high transfection efficiency. It is widely utilized for protein expression, virus production, and functional genomics studies, ensuring reproducibility across diverse assay platforms.

Protocadherin-9 is a calcium-dependent transmembrane adhesion molecule that mediates homophilic cell-cell contacts. It interacts with catenins, including beta-catenin and p120 catenin, to influence Wnt/beta-catenin signaling and Rho family GTPases such as RAC1 and CDC42. Loss of PCDH9 disrupts these interactions, potentially altering beta-catenin localization, TCF/LEF transcriptional activity, and actin cytoskeletal dynamics driven by Rho GTPases.

In HEK293T cells, the knockout enables dissection of adhesion-dependent signaling in a system expressing core Wnt and MAPK/ERK pathway components. This host background supports rescue experiments, luciferase reporter assays, and co-expression studies, allowing exploration of PCDH9??s role downstream of WNT ligands and Frizzled receptors and its impact on transcription and cytoskeletal organization.

Applications include cell adhesion and migration/invasion assays, co-immunoprecipitation with beta-catenin or NHERF1, TOP/FOP Flash reporter assays for Wnt activity, and actin staining. The line is relevant to cancer biology, neurodevelopmental disorder research, and tumor suppressor studies. For further information, please contact Ascent Research.